Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

被引：57

作者：

Gallwitz, Baptist ^{[1
]}

机构：

[1] Eberhard Karls Univ Tubingen, Dept Med 4, Otfried Mueller Str 10, D-72076 Tubingen, Germany

来源：

VASCULAR HEALTH AND RISK MANAGEMENT | 2007年 / 3卷 / 02期

关键词：

incretins; type; 2; diabetes; diabetes therapy; DPP-4; inhibitors; sitagliptin;

D O I：

10.2147/vhrm.2007.3.2.203

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Sitagliptin (Januvia (R), Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Sitagliptin is effective in lowering IIA1c, and fasting as well as postprandial glucose in monotherapy and in combination with other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion. In clinical studies it is weight neutral. This article gives an overview of the mechanism of action, the pharmacology, and the clinical efficacy and safety of sitagliptin in type 2 diabetes therapy.

引用

页码：203 / 210

页数：8

共 33 条

[11] Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes [J].

Feinglos, MN ;

Saad, MF ;

Pi-Sunyer, FX ;

An, B ;

Santiago, O .

DIABETIC MEDICINE, 2005, 22 (08) :1016-1023

[12]

Gallwitz B, 2006, Minerva Endocrinol, V31, P133

[13]

Herman G, 2006, DIABETOLOGIA, V49, P481

[14] Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes [J].

Herman, Gary A. ;

Bergman, Arthur ;

Yi, Bingming ;

Kipnes, Mark .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) :1939-1947

[15]

Karasik A, 2006, DIABETES, V55, pA119

[16] (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].

Kim, D ;

Wang, LP ;

Beconi, M ;

Eiermann, GJ ;

Fisher, MH ;

He, HB ;

Hickey, GJ ;

Kowalchick, JE ;

Leiting, B ;

Lyons, K ;

Marsilio, F ;

McCann, ME ;

Patel, RA ;

Petrov, A ;

Scapin, G ;

Patel, SB ;

Roy, RS ;

Wu, JK ;

Wyvratt, MJ ;

Zhang, BB ;

Zhu, L ;

Thornberry, NA ;

Weber, AE .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (01) :141-151

[17] Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor [J].

Knudsen, LB ;

Pridal, L .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 318 (2-3) :429-435

[18] Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26 [J].

Marguet, D ;

Baggio, L ;

Kobayashi, T ;

Bernard, AM ;

Pierres, M ;

Nielsen, PF ;

Ribel, U ;

Watanabe, T ;

Drucker, DJ ;

Wagtmann, N .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (12) :6874-6879

[19]

Meininger G, 2006, DIABETOLOGIA, V49, P5

[20] DIPEPTIDYLPEPTIDASE-IV HYDROLYZES GASTRIC-INHIBITORY POLYPEPTIDE, GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE, PEPTIDE HISTIDINE METHIONINE AND IS RESPONSIBLE FOR THEIR DEGRADATION IN HUMAN SERUM [J].

MENTLEIN, R ;

GALLWITZ, B ;

SCHMIDT, WE .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 214 (03) :829-835

← 1 2 3 4 →